{
    "clinical_study": {
        "@rank": "156574", 
        "arm_group": {
            "arm_group_label": "brentuximab vedotin (recombinant) Intravenous infusion", 
            "description": "Intravenous infusion of 1.8 mg/kg (body weight) of brentuximab vedotin (recombinant) administered once every three weeks"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety of brentuximab vedotin (recombinant) for\n      IV infusion (ADCETRIS IV Infusion 50 mg) in patients with relapsed/refractory CD30+\n      Hodgkin's lymphoma or anaplastic large cell lymphoma in the routine clinical setting, as\n      well as to collect efficacy information for reference."
        }, 
        "brief_title": "Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) \"Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma\"", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Hodgkin Disease", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphoma, Large-Cell, Anaplastic"
            ]
        }, 
        "detailed_description": {
            "textblock": "The present survey was designed to evaluate the safety of brentuximab vedotin (recombinant)\n      for IV infusion (ADCETRIS IV Infusion 50 mg) in patients with relapsed/refractory CD30+\n      Hodgkin's lymphoma or anaplastic large cell lymphoma in the routine clinical setting.\n\n      The usual adult dosage is 1.8 mg/kg (body weight) of brentuximab vedotin (recombinant)\n      infused intravenously once every three weeks. The dose should be adjusted depending on the\n      patient's condition. See the \"PRECAUTIONS\" section of the package insert."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All patients treated with ADCETRIS IV Infusion\n\n        Exclusion Criteria:\n\n          -  None"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Relapsed or refractory CD30+ Hodgkin's lymphoma or anaplastic large cell lymphoma"
            }
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02139592", 
            "org_study_id": "291-011", 
            "secondary_id": "JapicCTI-142513"
        }, 
        "intervention": {
            "arm_group_label": "brentuximab vedotin (recombinant) Intravenous infusion", 
            "description": "Brentuximab vedotin (recombinant) for IV infusion", 
            "intervention_name": "Brentuximab vedotin (recombinant)", 
            "intervention_type": "Drug", 
            "other_name": "ADCETRIS IV Infusion 50 mg"
        }, 
        "intervention_browse": {
            "mesh_term": "Antibodies, Monoclonal"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Pharmacological therapy", 
        "lastchanged_date": "May 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Osaka", 
                    "country": "Japan"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "ADCETRIS IV Infusion \u2212 Special Drug Use Surveillance (All-case Surveillance) \"Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma\"", 
        "overall_contact": {
            "email": "medicalinformation@tpna.com", 
            "last_name": "Takeda Study Registration Call Center", 
            "phone": "+1-800-778-2860 (USA & EU)"
        }, 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Postmarketing Group Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The frequencies of all adverse events observed during the observation period will be tabulated by type and seriousness. Adverse events are defined as unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product, regardless of relationship to the medicinal product.", 
            "measure": "Frequency of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "From the start of this drug uoto 48 weeks or until discontinuation of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02139592"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Based on findings of neck, chest, abdominal, and pelvic computed tomography and positron emission tomography, and in accordance with evaluation criteria for antitumor efficacy, the antitumor efficacy (best response) of ADCETRIS will be assessed as one of the following: complete response, unconfirmed complete response (when no PET data are available), partial response, stable disease, or progressive disease.", 
                "measure": "Antitumor efficacy (best response)", 
                "safety_issue": "No", 
                "time_frame": "From the start of this drug up to 48 weeks or until discontinuation of treatment"
            }, 
            {
                "description": "Time to death (regardless of cause of death) will be caluculated using Kaplan-Meier method.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "From the start of this drug up to 48 weeks  or until discontinuation of treatment"
            }
        ], 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}